Latest News about ROIV
Recent news which mentions ROIV
4 Analysts Assess Roivant Sciences: What You Need To Know
September 11, 2024
Tickers
ROIV
From Benzinga
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
September 10, 2024
From Benzinga
From Benzinga
Tickers
ROIV
From InvestorPlace
From Benzinga
From InvestorPlace
From InvestorPlace
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
March 29, 2024
From Benzinga
5 Value Stocks In The Healthcare Sector
February 19, 2024
From Benzinga
Earnings Scheduled For February 13, 2024
February 13, 2024
From Benzinga
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
January 10, 2024
From Benzinga
Assessing Roivant Sciences: Insights From 5 Financial Analysts
January 02, 2024
Tickers
ROIV
From Benzinga
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
December 21, 2023
From Benzinga
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
December 20, 2023
From Benzinga
Earnings Scheduled For November 13, 2023
November 13, 2023
From Benzinga
From Motley Fool
FSR Stock Alert: What to Know as Fisker Drops Prices
October 23, 2023
From InvestorPlace
PINS Stock Pops as Stifel Upgrades Pinterest
October 23, 2023
From InvestorPlace
Why Is Roivant Sciences (ROIV) Stock Up Today?
October 23, 2023
From InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.